BioCentury | Jun 16, 2017
Clinical News

Merck team ties PD-L2 to immunotherapy response

...clinical benefit to cancer patients. At least one therapy targeting PD-L2 has reached the clinic: AMP-224...
...Fc portion of IgG, and it has completed a Phase I trial to treat cancer. Mary Romeo AMP-224 Keytruda AstraZeneca...
BioCentury | Sep 1, 2016
Translation in Brief

Malaria's checkpoint sister

...LLC unit of AstraZeneca plc (LSE:AZN; NYSE:AZN) and GSK conducted a Phase I trial of AMP-224...
BioCentury | May 29, 2014
Distillery Therapeutics

Indication: Inflammation

...include determining whether the PD-L2-RGMB interaction can be targeted for cancer immunotherapy. AstraZeneca plc has AMP-224...
BioCentury | Jan 13, 2014
Finance

Buyside View XXII: 'Grown up' means growth

...Phase I testing for solid tumors: MEDI4736 , a human IgG1 mAb targeting PD-L1; and AMP-224...
...ligand 2 ( PDCD1LG2 ; B7-DC ; PD-L2 ) and the Fc portion of IgG. AMP-224...
BioCentury | Sep 9, 2013
Product Development

Checkpoint complementarity

...license to AMP-224 , a fusion protein that blocks the interaction between PD-1 and PD-L1. AMP-224...
BioCentury | Sep 2, 2013
Company News

Amplimmune, AstraZeneca deal

...end. The deal is expected to close this quarter. Amplimmune's most advanced partnered compound is AMP-224...
BioCentury | Aug 27, 2013
Company News

MedImmune to acquire Amplimmune

...cancer. The deal is expected to close this quarter. Amplimmune's most advanced partnered compound is AMP-224...
BioCentury | Jun 18, 2012
Product Development

Immune springboard

...SIX:NOVN) Lucatumumab (HCD122) Human mAb against CD40 Lymphoma Ph I/II Amplimmune Inc./GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) AMP-224...
BioCentury | Aug 19, 2010
Distillery Therapeutics

Indication: Infectious disease

...Ltd. and Bristol-Myers Squibb Co., is in Phase I testing to treat cancer and HCV. AMP-224...
BioCentury | Aug 9, 2010
Company News

Amplimmune, GlaxoSmithKline deal

...Amplimmune granted GlaxoSmithKline an exclusive, worldwide license to develop and commercialize AMP-224 and other next-generation fusion...
...Phase I trial of AMP-224 to treat cancer, which is slated to start next year. AMP-224...
...development to treat infectious disease. GSK is responsible for all further manufacturing, development and commercialization. AMP-224...
Items per page:
1 - 10 of 15